In a move that may boost to the pharma industry's reputation in poor countries, the international industry association has backed UK government calls to extend the deadline within which these countries must comply with the intellectual property rules in the World Trade Organization's TRIPS agreement. It is not yet clear what the new deadline will be.
In a move that may boost to the pharma industry's reputation in poor countries, the international industry association has backed UK government calls to extend the deadline within which these countries must comply with the intellectual property rules in the World Trade Organization's TRIPS agreement. It is not yet clear what the new deadline will be.
TRIPS took effect in 1995 for developed countries, but least-developed countries (LDCs) were given a transition period before they had...
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
